Tim Ferriss on psilocybin: philanthropy meets promising but unfinished science
Ferriss has funded psychedelic research and tied the work to depression, addiction, and trauma; the strongest claims still depend on controlled trials.
The Statement
This is something I've been working on for about 1.5 years.
Source: Tim Ferriss blog and philanthropy interviews (episode announcement).
Context
Ferriss has been a major philanthropic supporter of psychedelic science, including research centers studying psilocybin, addiction, depression, PTSD, and related conditions. He helped fund the Johns Hopkins Center for Psychedelic and Consciousness Research, which launched in 2019 with roughly $17 million in private donations, and has backed psychedelic research at Imperial College London as well. His podcast and writing have done as much as any single media figure to move psilocybin from fringe to mainstream conversation. Philanthropy and reach, though, are not the same as clinical endorsement — funding a trial does not pre-decide its result.
What The Evidence Shows
Modern psilocybin trials show promising signals for depression in controlled settings with preparation and support. The field still needs larger trials, durability data, and clearer access pathways. The most-cited result is COMPASS Pathways' COMP360 Phase 2b trial — 233 patients with treatment-resistant depression — where a single 25 mg dose with psychological support produced a significant drop in depression scores at three weeks versus a 1 mg comparator (published in the New England Journal of Medicine in 2022). Phase 3 trials are underway. Even so, psilocybin is still investigational: it holds an FDA Breakthrough Therapy designation but is not approved, and durability beyond a few months and the exact role of the therapy component remain open questions. Outside clinical trials, the only supervised legal access in the U.S. is through state-regulated programs in Oregon and Colorado. See our <a href='/guides/psilocybin'>psilocybin guide</a> for the current evidence and access map.
Where It Lands
Psilocybin is being seriously studied for depression.
Multiple academic and commercial programs have studied psilocybin-assisted treatment for depressive disorders.
Existing evidence is enough for broad unsupervised use.
Trials use screening, dosing controls, and support that are absent from self-treatment.
Ferriss personally takes psilocybin as treatment.
His public statements describe funding research and interviewing scientists and patients; they are not a claim about his own personal use, and this commentary does not treat them as one.
Bottom Line
Ferriss is accurately pointing to serious research momentum. That does not make psilocybin a general-purpose depression treatment outside regulated care or trials. The honest summary: the science is real, accelerating, and still unfinished. Unsupervised self-treatment skips the screening, dosing controls, and integration support that every positive trial relied on — which is exactly where the risk lives.
Frequently asked questions
How much has Tim Ferriss donated to psilocybin research?
Ferriss was a lead donor behind the roughly $17 million in private funding that launched the Johns Hopkins Center for Psychedelic and Consciousness Research in 2019, and he has also backed psychedelic research at Imperial College London. The exact split of his personal contribution versus other donors' has not been publicly itemized.
Is psilocybin FDA-approved for depression?
No. Psilocybin holds FDA Breakthrough Therapy designation, which speeds up the review process, but it is not an approved drug. The most-cited Phase 2b result (COMPASS Pathways' COMP360 trial, 233 patients, published in NEJM in 2022) showed a significant depression-score drop at three weeks after a single 25 mg dose with psychological support. Phase 3 trials, which determine approval, were still underway as of this review.
Where can someone legally access supervised psilocybin therapy in the US?
Outside of a clinical trial, the only state-regulated legal access is through Oregon's Measure 109 service centers and Colorado's Proposition 122 healing centers. Both require a trained facilitator and a supervised session; neither is FDA-approved medical treatment. See our psilocybin guide for the current access map.
Editorial commentary. Not medical or legal advice. Not endorsed by or affiliated with Tim Ferriss.